Skip to main content
Article thumbnail
Location of Repository

The role of endothelial cell reactive antibodies in peripheral arterial disease

By Nigel J. Lindsey, J.D. Armitage and Shervanthi Homer-Vanniasinkam


NoObjectives\ud It is hypothesised that endothelial cell reactive antibodies (ECRA) play a role in the progression of PAD through activation of endothelial cells and the release of inflammatory cytokines. We aimed to test this hypothesis by assessing levels of ECRA, E-selectin and IL-6 in patients with PAD of varying severity in a case controlled study.\ud \ud Design, materials, methods\ud Patients were assessed clinically and with ankle¿brachial pressure indices. Patients with critical ischaemia (CI, n=30), stable claudicants (SC, n=30), and age-matched controls (AMC, n=20) were studied. Antibody, E-selectin and IL-6 levels were measured using ELISA.\ud \ud Results\ud ECRA levels were significantly raised in the CI group over AMC.\ud \ud IL-6 levels were significantly elevated in both SC and CI over the control group and in CI over SC.\ud \ud There were no significant differences in E-selectin levels between the AMC, SC and CI.\ud \ud Conclusion\ud Our findings support the hypothesis that autoantibodies play a role in promoting PAD by elevating IL-6. The absence of an elevation in E-selectin in this study may be due to its short half-life, and casts doubt on its value as a marker of inflammation in atherosclerosis

Topics: Ischaemia, Peripheral vascular disease, Endothelial cell reactive antibodies, Peripheral arterial disease, Anticardiolipin, Anti-ß2-glycoprotein I, Interleukin-6
Year: 2006
DOI identifier: 10.1016/j.ejvs.2005.05.044
OAI identifier:
Provided by: Bradford Scholars
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.